Relevance of interferon-inducible protein-16 rather than anti-interferon-inducible protein-16 autoantibodies as a clinical and pathogenic biomarker in primary Sjogren
tissue. In addition, they suggested that IFI16 autoreactivity, essentially directed against an epitope outside the N-terminus, at least in patients with high-titer antiIFI16 autoantibodies, is triggered by elevated IFI16 protein expression in the glands of these patients as detected by immunoblotting in glandular tissue lysates. These results are in agreement with our previously published data showing increased serum levels of both antiIFI16 and IFI16 protein in primary SS patients (2). Our immunohistologic findings also confirmed that IFI16 protein, unlike in normal subjects and those with aspecific sialadenitis, is highly expressed in the salivary gland tissue of these patients with cytoplasmic mislocalization in acinar and ductal epithelium, peri-/intralesional endothelium, and infiltrating T cells. We believe, however, that the suggested association of anti-IFI16 with disease severity in primary SS deserves some comments. Several clinical, serologic, and histologic elements have been proposed as primary SS disease severity markers in the last years (3 6). However, Schirmer's test is not usually included among these since its positive correlation with glandular infiltration severity is rather poor. Although hypergammaglobulinemia represents a marker of B cell activation and, therefore, can be considered an expression of more active disease, the cutoff employed to identify pathologic values in validated criteria (7) is usually higher (IgG levels 1,600 mg/dl) than that used in the study by Baer et al (1,445 mg/dl), thereby making their data possibly unreliable.
Finally, anti-Ro/La autoantibodies, rather than ANAs, are considered highly specific for primary SS, are recognized for their ability to recognize Ro/La autoantigens at the glandular level, and are reliable markers of more severe disease and risk of lymphoma development (6) . In this setting, the arbitrarily high cutoff of ANA positivity chosen by Baer and colleagues (1:320, and not the usually employed suggested a protective rather than proinflammatory role of anti-IFI16 autoantibodies (8, 9) . On the contrary, there is consistent evidence for a pathogenic role of IFI16 protein in triggering and perpetuating inflammation in some chronic inflammatory and autoimmune rheumatic disorders (10) .
This fits with the IFI16 overexpression and mislocalization we found in the key cellular players of primary SS, where the main inflammatory process takes place and where the IFI16 protein may act as autoantigen in favoring B cell autoreactivity. In this context, therefore, the association of anti-IFI16 and major glandular infiltration found by Baer and colleagues is not so surprising.
In conclusion, we acknowledge the authors for their interesting results confirming our findings.
However, we believe that any definitive conclusion regarding the association between IFI16 autoantibodies and disease severity in primary SS should be drawn with caution. Actually, according to the data described in a number of studies, including those found by Baer et al and us, the IFI16 protein, rather than anti-IFI16 autoantibodies, may represent a relevant target for future investigations focused on pathogenic processes and clinical biomarkers in primary SS.
